Berkshire Hathaway Reduces Stake in DaVita Following Share Repurchase Agreement

Warren Buffett's firm sold over $35 million in shares as DaVita forecasts lower-than-expected 2025 earnings.

Berkshire Hathaway sold 203,091 shares of DaVita on February 11, reducing its stake to 45% as part of a prearranged share repurchase agreement.
The transaction was valued at approximately $35.96 million, based on DaVita's closing stock price on February 13.
DaVita's 2025 earnings guidance fell short of Wall Street expectations, projecting adjusted EPS between $10.20 and $11.30 versus analysts' average estimate of $11.24.
The company reported fourth-quarter adjusted earnings of $2.24 per share, exceeding analysts' expectations of $2.13 per share.
DaVita faced increased patient care costs, including $24.2 million in expenses tied to the closure of U.S. dialysis centers in the fourth quarter.